

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Bernard DUJON et al. ) **Prior application: 09/196,131**  
Serial No.: To be assigned ) **Group Art Unit: Unknown**  
Filed: April 18, 2001 ) **Examiner: Unknown**

For: NUCLEOTIDE SEQUENCE ENCODING  
THE ENZYME I-SCEI AND THE USES THEREOF

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Prior to the examination of the above application, please amend this application  
as follows:

**IN THE SPECIFICATION:**

On page 5, replace the paragraph beginning on line 4 with the following new  
paragraph:

-- Accordingly, this invention aids in fulfilling these needs in the art. Specifically,  
this invention relates to an isolated DNA encoding the enzyme I-SceI. The DNA has  
the following nucleotide sequence:

```

                ATG CAT ATG AAA AAC ATC AAA AAA AAC CAG GTA ATG 2670
                M   H   M   K   N   I   K   K   N   Q   V   M   12
2671 AAC CTC GGT CCG AAC TCT AAA CTG CTG AAA GAA TAC AAA TCC CAG CTG ATC GAA CTG AAC 2730
    13 N   L   G   P   N   S   K   L   L   K   E   Y   K   S   Q   L   I   E   L   N   32
2731 ATC GAA CAG TTC GAA GCA GGT ATC GGT CTG ATC CTG GGT GAT GCT TAC ATC CGT TCT CGT 2790
    33 I   E   Q   F   E   A   G   I   G   L   I   L   G   D   A   Y   I   R   S   R   52
2791 GAT GAA GGT AAA ACC TAC TGT ATG CAG TTC GAG TGG AAA AAC AAA GCA TAC ATG GAC CAC 2850
    53 D   E   G   K   T   Y   C   M   Q   F   E   W   K   N   K   A   Y   M   D   H   72
```

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

```

2851 GTA TGT CTG CTG TAC GAT CAG TGG GTA CTG TCC CCG CCG CAC AAA AAA GAA CGT GTT AAC 2910
    73 V  C  L  L  Y  D  Q  W  V  L  S  P  P  H  K  K  E  R  V  N  92

2911 CAC CTG GGT AAC CTG GTA ATC ACC TGG GGC GCC CAG ACT TTC AAA CAC CAA GCT TTC AAC 2770
    93 H  L  G  N  L  V  I  T  W  G  A  Q  T  F  K  H  Q  A  F  N  112

2971 AAA CTG GCT AAC CTG TTC ATC GTT AAC AAC AAA AAA ACC ATC CCG AAC AAC CTG GTT GAA 3030
    113 K  L  A  N  L  F  I  V  N  N  K  K  T  I  P  N  N  L  V  E  132

3031 AAC TAC CTG ACC CCG ATG TCT CTG GCA TAC TGG TTC ATG GAT GAT GGT GGT AAA TGG GAT 3090
    133 N  Y  L  T  P  M  S  L  A  Y  W  F  M  D  D  G  G  K  W  D  152

3091 TAC AAC AAA AAC TCT ACC AAC AAA TCG ATC GTA CTG AAC ACC CAG TCT TTC ACT TTC GAA 3150
    153 Y  N  K  N  S  T  N  K  S  I  V  L  N  T  Q  S  F  T  F  E  172

3151 GAA GTA GAA TAC CTG GTT AAG GGT CTG CGT AAC AAA TTC CAA CTG AAC TGT TAC GTA AAA 3210
    173 E  V  E  Y  L  V  K  G  L  R  N  K  F  Q  L  N  C  Y  V  K  192

3211 ATC AAC AAA AAC AAA CCG ATC ATC TAC ATC GAT TCT ATG TCT TAC CTG ATC TTC TAC AAC 3270
    193 I  N  K  N  K  P  I  I  Y  I  D  S  M  S  Y  L  I  F  Y  N  212

3271 CTG ATC AAA CCG TAC CTG ATC CCG CAG ATG ATG TAC AAA CTG CCG AAC ACT ATC TCC TCC 3330
    213 L  I  K  P  Y  L  I  P  Q  M  M  Y  K  L  P  N  T  I  S  S  232

3331 GAA ACT TTC CTG AAA TAA (SEQ ID NO:1)
    233 E  T  F  L  K  * (SEQ ID NO:2). --

```

On page 7, beginning on line 2 and ending at the bottom of the page, replace paragraphs 1-11 with the following new paragraphs:

-- This invention will be more fully described with reference to the drawings in which:

Fig. 1 depicts the universal code equivalent of the mitochondrial I-SceI gene (SEQ ID NO:1).

Fig. 2 depicts the nucleotide sequence of the invention encoding the enzyme I-SceI and the amino acid sequence of the natural I-SceI enzyme (SEQ ID NOS: 5 and 2).

Fig. 3 depicts the I-SceI recognition sequence and indicates the possible base mutations in the recognition site and the effect of such mutations on stringency of recognition (SEQ ID NOS: 6, 7, and 8).

Fig. 4 is the nucleotide sequence and deduced amino acid sequence of a region of plasmid pSCM525. The nucleotide sequence of the invention encoding the enzyme I-SceI is enclosed in the box (SEQ ID NOS: 9 through 16).

Fig. 5 depicts variations around the amino acid sequence of the enzyme I-SceI (SEQ ID NO: 2).

Fig. 6 shows Group I intron encoding endonucleases and related endonucleases (SEQ ID NOS: 17-44).

Fig. 7 depicts yeast expression vectors containing the synthetic gene for I-SceI.

Fig. 8 depicts the mammalian expression vector PRSV I-SceI.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

Fig. 9 is a restriction map of the plasmid pAF100. (See also YEAST, 6:521-534, 1990, which is relied upon and incorporated by reference herein).

Figs. 10A and 10B show the nucleotide sequence and restriction sites of regions of the plasmid pAF100 (SEQ ID NOS: 45-50). --

On page 12, replace the last paragraph with the following new paragraph:

-- The enzyme I-SceI has a known recognition site. (ref. 14.) The recognition site of I-SceI is a non-symmetrical sequence that extends over 18 bp as determined by systematic mutational analysis. The sequence reads: (arrows indicate cuts)

```

      ↓
5'   TAGGGATAACAGGGTAAT   3' (SEQ ID NO:51)
3'   ATCCCTATTGTCCCATTA   5' (SEQ ID NO:52). --
      ↑

```

On pages 41 to 42, replace the bridging paragraph with the following:

-- -e- The supernatant of this clone was used to infect other mouse cells (1009) by spreading  $10^5$  virus particles on  $10^5$  cells in DMEM medium with 10% fetal calf serum and 5 mg/ml of "polybrene" (hexadimethrine bromide). Medium was replaced 6 hours after infection by the same fresh medium. --

After page 52, and before page 53, please insert the attached pages titled "SEQUENCE LISTING".

### IN THE CLAIMS

Please cancel claims 1-26.

Please add the following new claims:

--27. A method for *in vivo* site directed genetic recombination in an organism comprising:

(a) providing a transgenic cell having at least one HO endonuclease or Group I intron encoded endonuclease recognition site inserted at a unique location in a chromosome;

(b) providing an expression vector that expresses said endonuclease in said transgenic cell;

(c) providing a plasmid comprising a gene of interest and a DNA sequence homologous to the sequence of the chromosomal DNA, allowing homologous recombination;

(d) transfecting said transgenic cell with said plasmid of step (c);

(e) expressing said endonuclease from said expression vector in said cell; and

(f) cleaving said endonuclease recognition site with said endonuclease, whereby said cleavage promotes the insertion of said gene of interest into said chromosome of said organism at a specific site by homologous recombination.

28. The method of claim 27, wherein said endonuclease recognition site has been introduced into said cells by homologous recombination.

29. The method of claim 27, wherein said endonuclease recognition site has been introduced into said cells by retroviral insertion.

30. The method of claim 27, wherein said organism is yeast.

31. The method of claim 27, wherein said organism is bacteria.

32. The method of claim 27, wherein said organism is a mammal.

33. The method of claim 27, wherein said endonuclease site is a Group I intron encoded endonuclease site.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

37. The method of claim 36, wherein said endonuclease recognition site is an I-SceI site. --

Applicants request the use of the computer-readable form of the Sequence Listing in U.S. Application Serial No. 08/417,226, filed April 5, 1995, now U.S. Patent No. 5,962,327, issued October 5, 1999.

I hereby state that the contents of the paper copy of the Sequence Listing in this application and the computer-readable form of the Sequence Listing in U.S. Application Serial No. 08/417,226, filed April 5, 1995, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with Markings to Show Changes Made.**"

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 18, 2001

By: 

Salvatore J. Arrigo

Reg. No. 46,063

Tel: (202) 408-4000

Fax: (202) 408-4400

Email: arrigos@finnegan.com

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

**Version with Markings to Show Changes Made****In the Specification:**

The paragraph beginning on line 4 of page 5 has been amended as follows:

Accordingly, this invention aids in fulfilling these needs in the art. Specifically, this invention relates to an isolated DNA encoding the enzyme I-SceI. The DNA has the following nucleotide sequence:

	ATG	CAT	ATG	AAA	AAC	ATC	AAA	AAA	AAC	CAG	GTA	ATG	2670								
	M	H	M	K	N	I	K	K	N	Q	V	M	12								
2671	AAC	CTC	GGT	CCG	AAC	TCT	AAA	CTG	CTG	AAA	GAA	TAC	AAA	TCC	CAG	CTG	ATC	GAA	CTG	AAC	2730
13	N	L	G	P	N	S	K	L	L	K	E	Y	K	S	Q	L	I	E	L	N	32
2731	ATC	GAA	CAG	TTC	GAA	GCA	GGT	ATC	GGT	CTG	ATC	CTG	GGT	GAT	GCT	TAC	ATC	CGT	TCT	CGT	2790
33	I	E	Q	F	E	A	G	I	G	L	I	L	G	D	A	Y	I	R	S	R	52
2791	GAT	GAA	GGT	AAA	ACC	TAC	TGT	ATG	CAG	TTC	GAG	TGG	AAA	AAC	AAA	GCA	TAC	ATG	GAC	CAC	2850
53	D	E	G	K	T	Y	C	M	Q	F	E	W	K	N	K	A	Y	M	D	H	72
2851	GTA	TGT	CTG	CTG	TAC	GAT	CAG	TGG	GTA	CTG	TCC	CCG	CCG	CAC	AAA	AAA	GAA	CGT	GTT	AAC	2910
73	V	C	L	L	Y	D	Q	W	V	L	S	P	P	H	K	K	E	R	V	N	92
2911	CAC	CTG	GGT	AAC	CTG	GTA	ATC	ACC	TGG	GGC	GCC	CAG	ACT	TTC	AAA	CAC	CAA	GCT	TTC	AAC	2770
93	H	L	G	N	L	V	I	T	W	G	A	Q	T	F	K	H	Q	A	F	N	112
2971	AAA	CTG	GCT	AAC	CTG	TTC	ATC	GTT	AAC	AAC	AAA	AAA	ACC	ATC	CCG	AAC	AAC	CTG	GTT	GAA	3030
113	K	L	A	N	L	F	I	V	N	N	K	K	T	I	P	N	N	L	V	E	132
3031	AAC	TAC	CTG	ACC	CCG	ATG	TCT	CTG	GCA	TAC	TGG	TTC	ATG	GAT	GAT	GGT	GGT	AAA	TGG	GAT	3090
133	N	Y	L	T	P	M	S	L	A	Y	W	F	M	D	D	G	G	K	W	D	152
3091	TAC	AAC	AAA	AAC	TCT	ACC	AAC	AAA	TCG	ATC	GTA	CTG	AAC	ACC	CAG	TCT	TTC	ACT	TTC	GAA	3150
153	Y	N	K	N	S	T	N	K	S	I	V	L	N	T	Q	S	F	T	F	E	172
3151	GAA	GTA	GAA	TAC	CTG	GTT	AAG	GGT	CTG	CGT	AAC	AAA	TTC	CAA	CTG	AAC	TGT	TAC	GTA	AAA	3210
173	E	V	E	Y	L	V	K	G	L	R	N	K	F	Q	L	N	C	Y	V	K	192
3211	ATC	AAC	AAA	AAC	AAA	CCG	ATC	ATC	TAC	ATC	GAT	TCT	ATG	TCT	TAC	CTG	ATC	TTC	TAC	AAC	3270
193	I	N	K	N	K	P	I	I	Y	I	D	S	M	S	Y	L	I	F	Y	N	212
3271	CTG	ATC	AAA	CCG	TAC	CTG	ATC	CCG	CAG	ATG	ATG	TAC	AAA	CTG	CCG	AAC	ACT	ATC	TCC	TCC	3330
213	L	I	K	P	Y	L	I	P	Q	M	M	Y	K	L	P	N	T	I	S	S	232
3331	GAA	ACT	TTC	CTG	AAA	TAA															
233	E	T	F	L	K	*															

(SEQ ID NO:1)  
(SEQ ID NO:2).

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

On page 7 beginning at line 2, paragraphs 1-11 have been amended as follows:

This invention will be more fully described with reference to the drawings in which:

Fig. 1 depicts the universal code equivalent of the mitochondrial I-SceI gene (SEQ ID NO:1).

Fig. 2 depicts the nucleotide sequence of the invention encoding the enzyme I-SceI and the amino acid sequence of the natural I-SceI enzyme (SEQ ID NOS: 5 and 2).

Fig. 3 depicts the I-SceI recognition sequence and indicates the possible base mutations in the recognition site and the effect of such mutations on stringency of recognition (SEQ ID NOS: 6, 7, and 8).

Fig. 4 is the nucleotide sequence and deduced amino acid sequence of a region of plasmid pSCM525. The nucleotide sequence of the invention encoding the enzyme I-SceI is enclosed in the box (SEQ ID NOS: 9 through 16).

Fig. 5 depicts variations around the amino acid sequence of the enzyme I-SceI (SEQ ID NO: 2).

Fig. 6 shows Group I intron encoding endonucleases and related endonucleases (SEQ ID NOS: 17-44).

Fig. 7 depicts yeast expression vectors containing the synthetic gene for I-SceI.

Fig. 8 depicts the mammalian expression vector PRSV I-SceI.

Fig. 9 is a restriction map of the plasmid pAF100. (See also YEAST, 6:521-534, 1990, which is relied upon and incorporated by reference herein).

Figs. 10A and 10B show the nucleotide sequence and restriction sites of regions of the plasmid pAF100 (SEQ ID NOS: 45-50).

On page 12, the last paragraph has been amended as follows:

The enzyme I-SceI has a known recognition site. (ref. 14.) The recognition site of I-SceI is a non-symmetrical sequence that extends over 18 bp as determined by systematic mutational analysis. The sequence reads: (arrows indicate cuts)

↓

5'	TAGGGATAACAGGGTAAT	3'	(SEQ ID NO:51)
3'	ATCCCTATTGTCCCATTA	5'	(SEQ ID NO:52)

↑

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000



On pages 41 to 42, the bridging paragraph has been amended as follows:

-e- The supernatant of this clone was used to infect other mouse cells (1009) by spreading  $10^5$  virus particles on  $10^5$  cells in DMEM medium with 10% fetal calf serum and 5 mg/ml of "[polybrain] polybrene (hexadimethrine bromide)". Medium was replaced 6 hours after infection by the same fresh medium.

FILED IN 3495.0111-12

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000